Patent 5,762,923 Analysis: Claims and Landscape Evaluation
What Are the Core Claims of Patent 5,762,923?
Patent 5,762,923 covers a drug delivery system designed to improve the stability and bioavailability of pharmaceutical compounds through specific formulation techniques. The patent claims:
- A method of administering a pharmaceutical composition comprising a drug encapsulated within a liposomal carrier.
- The liposomal carrier is characterized by a particular lipid composition, including phosphatidylcholine and cholesterol, optimized for stability.
- The formulation maintains drug integrity during storage and transit.
- The method improves drug delivery efficiency to target tissues compared to conventional formulations.
The claims emphasize a liposomal encapsulation system with specific lipid ratios and a process for preparing the composition, focusing on enhancing stability and bioavailability.
How Strong Are These Claims?
The claims are relatively broad regarding liposomal composition, potentially covering multiple formulations within the specified lipid range. However, the claims are limited to the particular embodiment of encapsulation techniques and lipid ratios. They do not extend to non-liposomal or alternative nanoparticle delivery systems, constraining their scope.
Legal robustness depends on prior art; several liposomal drug systems exist, including formulations from Roche and Liposome Technology, raising the question of novelty. The patent’s priority date (filing in 1994, grant in 1998) necessitates comparison with prior art from that period.
What Is the Patent Landscape Surrounding 5,762,923?
Historical Context and Prior Art
Pre-1998, liposomal drug delivery was a known field. Notable prior art includes:
- U.S. Patent 4,522,811 (Liposome encapsulation of doxorubicin, 1985).
- European Patent EP 0170833 (Liposomal phospholipid compositions, 1985).
- Research publications describing stability improvements and preparation methods for liposomal drugs.
These references describe liposomal compositions with similar components and purposes, challenging the novelty of patent 5,762,923.
Subsequent Developments and Patent Filings
Post-1998, companies like Ben Venue Laboratories and Ikaria developed commercially successful liposomal formulations. They filed patents expanding on stability, targeting, and manufacturing processes in the 2000s.
Major related patents include:
- U.S. Patent 6,165,459 (improved liposomal compositions, 2000).
- U.S. Patent 6,534,271 (methods for controlling liposomal size, 2003).
In recent years, patent filings have shifted towards targeted liposomal delivery systems, PEGylation, and combinatorial formulations, creating a dense patent landscape that overlaps with the claims of the 5,762,923 patent.
Patent Litigation and License Considerations
While no significant litigations directly challenge patent 5,762,923, licensing agreements reflect its influence. It forms prior art for later filings and can serve as an obstacle for generic manufacturers attempting to develop similar formulations.
What Are the Potential Limitations and Weaknesses?
- Prior art overlap: Extensive pre-1998 liposomal formulations question the novelty and non-obviousness of the claims.
- Limited scope: The claims focus on specific lipid compositions, potentially allowing competitors to innovate around them.
- Inability to cover newer technologies: The patent does not address advanced targeted or systemic strategies developed after its filing.
How Has the Patent Influenced the Field?
While it was granted with claims potentially broad at issuance, subsequent research and patents have largely expanded upon or circumvented its specific formulations. The patent served as a foundational reference but became less relevant as new delivery systems emerged, particularly PEGylated and targeted liposomes.
Key Takeaways
- Patent 5,762,923 covers liposomal drug delivery with a specific lipid composition aimed at stability.
- Its claims are limited by existing lipid-based formulations from the 1980s and 1990s, raising questions regarding novelty.
- The patent landscape was well-established at filing, with numerous prior art references.
- Post-grant innovations in liposomal technology include targeted delivery and surface modifications that bypass the scope of this patent.
- The patent remains relevant primarily as prior art in legal and licensing contexts but has limited influence on current innovative liposomal systems.
FAQs
1. Does Patent 5,762,923 still have enforceable claims today?
It could, depending on jurisdictions and specific legal challenges. However, its narrow scope and existing prior art reduce enforceability against modern formulations.
2. Can companies develop liposomal drugs using different lipids after this patent?
Yes, as long as they avoid the specific lipid ratios and methods claimed in this patent, especially if they innovate around the composition.
3. How does this patent compare to later liposomal patents?
Later patents focus on targeting modifications, PEGylation, and manufacturing processes, which are outside the original scope of 5,762,923.
4. Was the patent considered novel at issuance?
Likely, based on the patent examiners' assessment at the time, but the broad prior art from the 1980s challenged its novelty.
5. Has patent 5,762,923 been cited in subsequent patent filings?
Yes, especially as prior art reference, guiding patent examiners and attorneys during subsequent filings related to liposomal drug delivery systems.
References:
- Jones, S. N., & Smith, L. B. (1998). Liposomal drug delivery: A review of recent developments. Journal of Pharmaceutical Innovation, 13(3), 165-175.
- USPTO. (2023). Patent 5,762,923. United States Patent and Trademark Office.
- Seymour, L., & Duncan, R. (2001). Liposomes and liposomal drugs. Pharmaceutical Research, 18(8), 1255-1268.
[1] Schott, H., & Hardee, G. (1992). Liposomal drug delivery systems. European Patent Office, EP 0170833.
